The future of heart health hangs in the balance, and two powerhouses are joining forces to tip the scales in our favor. The Society for Cardiovascular Angiography and Interventions (SCAI) and Cardiovascular Research Technologies (CRT) have just announced a groundbreaking partnership that promises to revolutionize interventional cardiology. But here's where it gets exciting: this isn't just about sharing resources—it's about merging distinct perspectives to tackle the field's most pressing challenges head-on. And this is the part most people miss: by combining SCAI's clinical expertise with CRT's research prowess, they're creating a synergy that could redefine how we approach heart disease treatment and prevention.
At the heart of this collaboration is a shared commitment to education, advocacy, and innovation. SCAI members will enjoy discounted registration for CRT 2026, where both organizations will co-host educational sessions, ensuring that the latest advancements reach the frontline practitioners. But here's the controversial bit: while some might argue that such partnerships could dilute individual organizational identities, SCAI and CRT are proving that collaboration can amplify impact without sacrificing uniqueness. In fact, they're doubling down on their strengths—SCAI will lead an annual 'Day on the Hill' legislative event in Washington, DC, tied to the CRT meeting, while CRT will provide core lab services for joint research initiatives.
Long-term, the partnership aims to explore novel registry and clinical trial programs, addressing gaps in interventional cardiology research. Here’s a thought-provoking question: Can this alliance truly bridge the gap between clinical practice and cutting-edge research, or will the complexities of collaboration slow down progress? The SCAI–CRT Task Force, composed of representatives from both organizations, will steer these efforts, identifying opportunities and ensuring seamless coordination. SCAI will also form a working group to evaluate research proposals, fostering a pipeline of innovative projects.
"Collaboration is the cornerstone of medical progress, especially in interventional cardiology," said Srihari S. Naidu, MD, MSCAI, president of SCAI. "While we approach our goals from different angles, this partnership reflects a growing alignment in vision. Together, we're not just aiming to improve patient outcomes—we're striving to set new standards in the field."
J. Dawn Abbott, MD, MSCAI, chair of the SCAI–CRT Partnership Task Force and president-elect of SCAI, added, "By combining our strengths, we can accelerate investigator-led research, expand professional development, and ultimately deliver better care for patients. This isn't just about what we can do today—it's about shaping the future of cardiovascular medicine."
Ron Waksman, MD, MSCAI, chair of the CRT meeting, emphasized the partnership's broader impact: "Through this collaboration, we're connecting clinical science, advocacy, and education in ways that will drive innovation. Our shared vision is to inspire the next generation of interventionalists and ensure that patients everywhere benefit from the rapid progress being made in the interventional lab."
But let’s not forget the elephant in the room: With great collaboration comes great responsibility. How will SCAI and CRT ensure that their joint efforts remain patient-centered and accessible to diverse populations? As they secure external funding and expand their research networks, will they prioritize inclusivity and equity? These are the questions that will define the success of this partnership—and we’re all ears for your thoughts in the comments. What do you think? Is this the kind of collaboration cardiology needs, or are there potential pitfalls we should be wary of?
